Nrx pharmaceuticals (nasdaq:nrxp) announces data-lock of phase 2b/3 trial of nrx-101 in suicidal treatment resistant bipolar depression

Data transferred for independent statistical analysis top-line data expected in april 2024 radnor, pa. , april 8, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced that the company has achieved data-lock in its phase 2b/3 suicidal treatment resistant bipolar depression study with nrx-101.
NRXP Ratings Summary
NRXP Quant Ranking